Menu Search
Equities

Biomerieux SA

EYWN:DEU

Biomerieux SA

Actions
  • Price (EUR)97.50
  • Today's Change-1.60 / -1.61%
  • Shares traded24.00
  • 1 Year change-0.57%
  • Beta--
Data delayed at least 15 minutes, as of Nov 25 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Biomerieux SA's net income fell -20.94% from 452.30m to 357.60m despite relatively flat revenues. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 26.60% to 27.77%.
Gross margin55.72%
Net profit margin10.48%
Operating margin13.65%
Return on assets7.71%
Return on equity10.98%
Return on investment9.57%
More ▼

Cash flow in EURView more

In 2023, cash reserves at Biomerieux SA fell by 195.30m. However, the company earned 445.40m from its operations for a Cash Flow Margin of 12.12%. In addition the company used 488.80m on investing activities and also paid 122.30m in financing cash flows.
Cash flow per share5.94
Price/Cash flow per share16.56
Book value per share32.80
Tangible book value per share22.25
More ▼

Balance sheet in EURView more

Biomerieux SA has a Debt to Total Capital ratio of 12.58%, a higher figure than the previous year's 9.10%.
Current ratio2.21
Quick ratio1.20
Total debt/total equity0.1444
Total debt/total capital0.1258
More ▼

Growth rates in EUR

SmartText is unavailable
Div yield(5 year avg)0.65%
Div growth rate (5 year)19.42%
Payout ratio (TTM)24.46%
EPS growth(5 years)6.76
EPS (TTM) vs
TTM 1 year ago		6.36
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.